Too often, recruiters are more clear on what a position will “do” rather than what it will “achieve”.Outlining tasks and responsibilities takes priority over goals and impact.But to attract top talent, you need to define and explain what success looks…
To read the full story
Related Article
- MHLW to Run Pilot Sale of Emergency Contraceptives without Prescription
June 29, 2023
- Citizens’ Group Opposes Pilot Switch Program for Emergency Contraceptives
June 27, 2023
- Will Pilot Switch Proposal Break Stalemate in Emergency Contraceptive Debate?
June 23, 2023
- MHLW Mulls New OTC Class to Bar Online Sales amid Unease over Morning After Pills
June 14, 2023
- LDP Lawmakers Oppose Online Sale of Morning After Pills 3 Years after Switch
June 8, 2023
- Japan Eyes Pilot Program for OTC-Switching of Emergency Contraceptives, Public Commenters Overwhelmingly Positive
May 18, 2023
- Rx-to-OTC Switching of Morning After Pills Needs Cautious Approach: Lawmakers
December 27, 2022
- MHLW to Reexamine Whether to Permit Sale of Emergency Contraceptives Without a Prescription
October 12, 2020
- OTC Switching of Emergency Contraceptive Levonorgestrel Will Be Difficult Under Current System: JPA
October 16, 2017
- MHLW Council Recommends Switching of 4 APIs; Switching of Levonorgestrel for Emergency Contraception Disapproved
July 28, 2017
REGULATORY
- LDP Lawmakers Call for Penalties against “Dump and Run Away” Generic Makers
March 29, 2024
- Beni-Koji Issue: MHLW Requests Self-Inspections to Purchasers of Kobayashi’s Red Rice Yeast
March 29, 2024
- Label Revision Ordered for CAR-T Therapies to Add New Precaution
March 29, 2024
- Japan PM Vows Early Kick Off of Off-Year Revision Debate at Chuikyo
March 29, 2024
- Japan Diet Passes FY2024 Budget, Record Social Security Spending
March 29, 2024
Pharmaceutical companies are giving high marks to Japan’s drug pricing reform for FY2024. According to a survey conducted by Jiho, 51% of all respondents expressed a positive opinion of the reform, saying that they were “somewhat satisfied” with it. The…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…